Karin von Dehn-Rothfelser

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
NV1020, an oncolytic herpes simplex virus type 1, can destroy colon cancer cells by selectively replicating within these cells, while sparing normal cells. NV1020 is currently under investigation in a clinical phase I/II trial as an agent for the treatment of colon cancer liver metastases, in combination with conventional chemotherapeutic agents such as(More)
  • 1